$NVMI

Oppenhaim Eitan sold $781K of NVMI

Oppenhaim Eitan sold 1,504 shares of NOVA LTD. (NVMI) at $519.48 ($0.78M total) on 2026-05-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Oppenhaim Eitan
Published May 27, 2026, 2:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 27, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$NVMI
Neutral
medium confidence
Mentioned
$NVMI
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NVMINeutralLow
01

Why it matters

Because the sale is explicitly pre-arranged, it is generally treated as lower-information than unscheduled selling; the main trading implication is sentiment/positioning rather than a fundamental change.

02

Market read

A disclosed director sale in NVMI under 10b5-1 is more likely a routine liquidity event than a new negative catalyst.

03

What to watch

The article provides only one sale; without context on prior insider activity, total insider net selling, and whether other executives also sold, directional inference is weak.

Relevance 6/10Timing: Immediate (same-day disclosure) but likely limited follow-through.

Background

This is a SEC Form 4 insider transaction: director Oppenhaim Eitan sold 1,504 NVMI shares for ~$781.3K on 2026-05-26 under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$NVMINeutralMedium confidence
Context

NOVA Ltd. (NVMI) disclosed an insider open-market sale by director Oppenhaim Eitan of 1,504 shares at $519.48 on 2026-05-26.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived and outweighed by broader fundamentals.

Evidence & confidence

Insider sales under Rule 10b5-1 are often pre-planned and may not reflect new negative information; the disclosed size is modest relative to typical liquidity, and no other company-specific catalyst is mentioned.

Market effects

Minimal—single insider sale without additional operational/regulatory updates offers little sector read-across.

None indicated; disclosure is company-specific.

None indicated beyond standard US insider reporting.

Counterpoint

Even with 10b5-1, repeated or accelerating insider sales can precede weaker sentiment; traders may still monitor for a trend across filings.

Key entities

  • NOVA Ltd.

    Company whose shares were sold by a director under a 10b5-1 plan (NVMI).

  • Oppenhaim Eitan

    Director who executed the open-market sale disclosed in the Form 4.

  • Rule 10b5-1 plan

    Pre-arranged plan that typically reduces the informational value of insider sales.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$NVMIMedAI 8/10

Nova (NVMI) Just Blew Past $250M In Quarterly Sales

Nova (NVMI) reported Q2 2026 revenue of $255M, up 8% QoQ and 16% YoY, with GAAP net income of $75M and non-GAAP net income of $86.5M. GAAP EPS was $2.20, up from $2.04 QoQ and $2.14 YoY. Non-GAAP EPS was $2.51, up from $2.33 QoQ and $2.20 YoY. The company guided Q3 2026 revenue to $277M-$287M, GAAP EPS to $2.46-$2.61, and non-GAAP EPS to $2.70-$2.85. Gross margin declined to 56.5% from 57.7% QoQ and 57.8% YoY.

$ESLTMed

Tue: Rate cut lifts market

The Tel Aviv Stock Exchange rose after the Bank of Israel cut interest rates to 3.25%. The Tel Aviv 35 Index gained 0.22%, while Dimri led gains with a 5.47% rise. OPC Energy fell 4.67%, the biggest decline. Key movers included Elbit Systems, Teva, and Ormat, which rose, and Camtek and Tower Semiconductor, which fell.

$NVMIHigh

NOVA LTD. (NVMI): Financial results for Q2 2026

NOVA LTD. (NVMI) furnished an SEC Form 6-K — earnings release. Attached hereto and incorporated by way of reference herein is a press release issued by the Registrant and entitled: “Nova Reports Record Second Quarter 2026 Financial Results”. The GAAP financial statements tables included in the press release attached hereto are hereby incorpo

$TEVAMed

Wed: Teva jumps but TASE continues to lose ground

Globes reports the Tel Aviv Stock Exchange fell on July 29, with the Tel Aviv 35 down 0.99% and Tel Aviv 125 down 0.96%. Teva Pharmaceutical (NYSE: TEVA; TASE: TEVA) rose 10.17% after Q2 results and raised revenue guidance. Other movers included Enlight Renewable Energy, Elbit Systems, and banks such as Bank Leumi and Hapoalim.